ClinicalTrials.gg
CompletedNCT05361005Updated May 4, 2022

Tolerability and Safety of BDB-001 Injection in Healthy Subjects

A Phase 1 interventional study of BDB-001 injection and Placebo in Healthy, sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-04.

Sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Mar 2020, registered Apr 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A clinical study to evaluate the tolerability, PK and PD characteristics of BDB-001 Injection in healthy subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Staidson (Beijing) Biopharmaceuticals Co., Ltd is the lead sponsor of 28 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between 18\~55 years old (including 18 and 55 years old);
  • A healthy subject evaluated by medical history etc;
  • Physical examination and vital signs normal, or abnormal without clinical significance;
  • Weight: 80 kg ≥ male ≥50 kg, and 80 kg ≥ female ≥45 kg. (BMI) between 18\~28kg/m2 (including 18 and 28). Body mass index (BMI) = body weight (kg) / height 2 (m2);
  • Be able to complete the study in compliance with protocol;
  • The subjects (including sex partners) willing to take effective measures within 6 months after the last dose. Refer to the appendix for the detailed contraceptive methods;
  • form signed prior to the study and the content, process and possible adverse reactions of the study fully understood.

Exclusion criteria

Exclusion Criteria:

  • More than 5 cigarettes were smoked daily within 3 months prior to screening period of the study;
  • Allergic history (drugs and food);
  • A history of drug abuse and / or drinking (drinking 14 units per week of alcohol: 1 unit = 285 mL beer, or liquor 25 mL, or wine 100ml);
  • Subjects who had donated blood or massive blood loss (> 450 mL) within 3 months prior to screening period, or those who had plasma exchange within 4 weeks prior to screening period;
  • Any prescription drugs, OTC drugs, any vitamin products or herbs were used within the 14 days prior to screening period, and immunomodulators were used within 28 days prior to screening period;
  • Subjects who had taken other product(s) or vaccine within 3 months prior to screening period, or those who were expected to be vaccinated within 2 months after completion of the study;
  • Vigorous exercise or other factors affecting drug absorption, distribution, metabolism, excretion within 2 weeks prior to screening;
  • Significant change in eating or exercise habits recently;
  • Subjects who have taken BDB-001 injection or participated in clinical trials of investigational drugs within three months prior to taking study drugs;
  • Subjects with a history of previous tuberculosis and exposure to active tuberculosis, TB-spot test results is greater than 2 UL(upper limit) of normal range, and those with infectious diseases recently;
  • Subjects with or immunodeficiency diseases, or with a family history of autoimmune diseases or immunodeficiency diseases;
  • Abnormal with clinical significance;
  • Female subjects are in the lactation period or have positive serum pregnancy results during the period of trial (from screening to completion);
  • Clinical laboratory examination result with clinical significance, or other clinical findings within 12 months prior to screening period with clinical significance ( including but not limited to gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor, lung, immune, mental or cardiovascular diseases);
  • Subjects whose white blood cell count, high-sensitivity C-reactive protein test results were abnormal with clinical significance during screening and baseline period (-1 day), : male \<120g/L or female \<110g/L;
  • Subjects with positive result of viral hepatitis (including and C), AIDS antibody, or treponema pallidum antibody;
  • Subjects with acute disease or with concomitant medication from the screening stage to the start time of drug administration;
  • Subjects with more than 5 cups (150mL cups) of coffee, tea or cola each day;
  • Subjects with any alcohol-containing products within 48 hours before taking study medication;
  • Subjects with a positive urine drug screening or with a history of drug abuse or drug use within the past five years;
  • The investigators suggested the subject was not suitable to participate in this study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Cohort 2mg/kg

    All participants (fasted) received either 2 mg/kg of BDB-001 as a single dose or dose-matched placebo.

    Drug: BDB-001 injection · Drug: Placebo

  • Experimental
    Cohort 4mg/kg

    All participants (fasted) received either 4 mg/kg of BDB-001 as a single dose or dose-matched placebo.

    Drug: BDB-001 injection · Drug: Placebo

  • Experimental
    Cohort 8mg/kg

    All participants (fasted) received either 8mg/kg of BDB-001 as a single dose or dose-matched placebo.

    Drug: BDB-001 injection · Drug: Placebo

  • Experimental
    Cohort 4mg/kg multiple doses

    All participants (fasted) received either 4 mg/kg of BDB-001 as a multiple doses or doses-matched placebo.

    Drug: BDB-001 injection · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events, Clinically Significant Laboratory Abnormalities, Clinically Significant Electrocardiogram Abnormalities, Clinically Significant Vital Signs Abnormalities And Clinically Significant Physical Examination Abnormalities

    Time frame: Up to 28 Days

  2. Maximum plasma concentration (Cmax)

    Time frame: Up to 504 hours postdose

  3. Area under the plasma concentration-time curve from time 0 to infinity (AUC0inf)

    Time frame: Up to 504 hours postdose

  4. Area under the plasma concentration-time curve from time 0 to 480hr(AUC00-480hr)

    Time frame: Up to 504 hours postdose

  5. Time of maximum concentration (Tmax)

    Time frame: Up to 504 hours postdose

  6. Elimination half-life (t1/2)

    Time frame: Up to 504 hours postdose

  7. Clearance (CL)

    Time frame: Up to 504 hours postdose

  8. Apparent volume of distribution (Vz)

    Time frame: Up to 504 hours postdose

  9. Mean residence time (MRT)

    Time frame: Up to 504 hours postdose

Secondary outcomes

  1. Change from baseline in concentration of free C5a and anti-drug antibody

    Time frame: Up to 504 hours postdose

07

Study locations

1 site
  • Shu Lan (Hangzhou) Hospital
    Hangzhou, Zhejiang 310022, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in May 2020, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2022
First posted
May 4, 2022
StartActual
Mar 12, 2020
Primary completionActual
May 8, 2020
CompletionActual
May 8, 2020
Last update
May 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05361005
Collaborators
Beijing Defengrei Biotechnology Co.,Ltd
Responsible party
Sponsor
First posted
May 4, 2022
Start date
Mar 12, 2020
Primary completion
May 8, 2020
Completion
May 8, 2020
Last update
May 4, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BDB001

Start the discussion